We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amneal Pharmaceuticals Holding Co | NYSE:AMRX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 5.87 | 0 | 01:00:00 |
From May 2023 to May 2024
By Will Feuer
Amneal Pharmaceuticals said it has received 505(b)(2) New Drug Application approval from the U.S. Food and Drug Administration for Pemrydi RTU, a ready-to-use presentation of pemetrexed, a type of chemotherapy, for injection.
The injectable doesn't require reconstitution, dilution or refrigeration. It will be available in three vial sizes, the company said. Amneal Pharmaceuticals said it expects to launch the product in the first quarter of 2024.
Shares rose 4.7% to $2.70 in premarket trading.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
June 14, 2023 08:44 ET (12:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Amneal Pharmaceuticals Chart |
1 Month Amneal Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
